Hitting the bull's eye: Targeting HMGA1 in cancer stem cells

Breann L. Yanagisawa, Linda M.S. Resar

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


Emerging evidence suggests that when cancer cells hijack normal stem cell properties, they acquire the ability to invade, metastasize to distant sites and evade therapy. Thus, eliminating cancer cells with stem cell properties, or cancer stem cells, is of prime importance for the successful treatment of cancer, regardless of the tissue of origin. Previous efforts to target cancer stem cells (CSCs), however, have been largely unsuccessful. Recent studies led to the discovery of a novel role for the high mobility group A1 (HMGA1) protein as a master regulator in both CSCs and normal embryonic stem cells. Here, we present exciting new work unveiling HMGA1 as a promising target for therapies directed at eradicating CSCs.

Original languageEnglish (US)
Pages (from-to)23-30
Number of pages8
JournalExpert Review of Anticancer Therapy
Issue number1
StatePublished - Jan 2014


  • HMGA1
  • cancer stem cells
  • embryonic stem cells
  • epithelial-mesenchymal transition
  • high mobility group A1 protein

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'Hitting the bull's eye: Targeting HMGA1 in cancer stem cells'. Together they form a unique fingerprint.

Cite this